Background: Heparan sulfate proteoglycan syndecan-4 plays an important role in inflammation. However, the role of syndecan-4 in rheumatoid arthritis (RA) has not yet been elucidated. Objectives: To detect serum level of syndecan-4 in RA patients and investigate its correlation with RA clinical parameters. Methods: The concentration of serum syndecan-4 was assayed by enzyme-linked immunosorbent assay (ELISA). 43 patients' serum samples from our RA cohort study between 2014 and 2016, and 20 age-and gender-matched osteoarthritis (OA) patients' serum samples were collected and analyzed. Compared the serum syndecan-4 levels in RA patients with DAS28≥3.2 and DAS28<3.2 by Wilcoxon signed rank test. The relationships between serum syndecan-4 levels and RA clinical parameters (DAS28, rheumatoid factor (RF), erythrocyte sedimentation rate, C-reactive protein, etc.) were analyzed. Results: Baseline serum syndecan-4 levels of RA patients were significantly higher than the matched OA patients (1101.56 pg/mL vs 281.41 pg/mL, p<0.001). In RA patients who had sera both at the point of DAS28≥3.2 and DAS28<3.2 (n=13), we found that the former syndecan-4 levels were higher than the latter (1666.22 pg/mL vs 1378.34 pg/mL, p=0.65). The levels of serum syndecan-4 and RF were significantly and positively correlated in RA patients (r=0.696, p=0.008). Furthermore, there is a tendency that serum syndecan-4 levels were higher in the RF-positive (n=31) than in the RF-negative (n=12) RA patients (1344.43 pg/mL vs 971.27 pg/mL, p=0.078).
Conclusions:
Compared with age-and gender-matched OA patients, serum syndecan-4 concentration is significantly higher in RA patients. Serum syndecan-4 level is positively correlated with RF. Syndecan-4 may play an important role in thes pathogenesis of RA. Further investigation is required to study the mechanism of syndecan-4 in RA. 
